Recent Updates
Recently added Catalysts

Levocetirizine DiHCl

Phase 1

Fasting | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jan 9, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment29
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01506076Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting ConditionsPHASE1 COMPLETED 29Dec 1, 2007Jan 1, 2008Jan 9, 20121 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence is based on Cmax and AUC parameters
2 month
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Levocetirizine DiHCl Tablets, 5 mgEXPERIMENTALLevocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
XYZALACTIVE_COMPARATORXYZAL Tablets 5 mg of UCB Farchim S.A.
Interventions
NameTypeDescription
Levocetirizine DiHClDRUGLevocetirizine DiHCl Tablets 5 mg
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subjects will provide written informed consent. * Subjects must be healthy adults within 18-45 years of age (inclusive). * Body mass index of ≥18.5 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg. * Subjects must be of normal health as determined by medical history a...

Countries:India
Unlock Eligibility Criteria